Tradestie Institutional Equity Comparison Engine
ATYR vs CCCC โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ATYR Overall Edge
ATYR Captures Institutional Edge (3โ0 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to aTyr Pharma, Inc. Common Stock (ATYR) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ATYR trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CCCC at N/M Forward P/E and -315.9% operating margin (-24.6% YoY). In options structure, ATYR sits in UNCLASSIFIED (36th %ile IV; Dealer Gamma Walls on Pro) against CCCC sits in BREAKDOWN (3rd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
ATYR N/M vs CCCC N/M Fwd P/E
Growth & Margin Winner
ATYR
Op Margin 0.0% vs -315.9% ยท YoY +0.0% vs -24.6%
Momentum & Technical Winner
ATYR
1Y +558.7% vs +3.4% ยท 52W Pos 62% vs 25%
Options & Structure Winner
ATYR
UNCLASSIFIED (36th %ile IV) vs BREAKDOWN (3rd %ile IV)
ATYR
NASDAQ
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap
$15.6M
1M Return
+2788.76%
1Y Return
+558.7%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 50.0
Fund 36.0
Flow 69.0
Mom 50.0
CCCC
NASDAQ
C4 Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$2.56
-3.58% 1D
Market Cap
$362.4M
1M Return
-11.59%
1Y Return
+3.44%
Forward P/E
N/M
Unified AI Score
47.7 / 100
HOLD
Tech 33.0
Fund 51.0
Flow 64.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ATYR +558.7%
CCCC +3.44%
Spread: +555.26 pp (ATYR Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | ATYR Revenue | CCCC Revenue | ATYR Op. Margin | CCCC Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $0M | N/A | -5445.0% | N/A | ATYR |
| FY2020 | $10M | N/A | -152.2% | N/A | ATYR |
| FY2021 | N/A | $50M | N/A | -179.4% | CCCC |
| FY2022 | $10M | $30M | -446.8% | -416.6% | CCCC |
| FY2023 | $0M | $20M | -15557.8% | -669.8% | CCCC |
| FY2024 | $0M | $40M | -28899.6% | -336.1% | CCCC |
| FY2025 | $0M | $40M | -40856.3% | -320.5% | CCCC |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ATYR | CCCC | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $15.6M | $362.4M | Larger Scale | CCCC |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -24.6% | Higher Growth | ATYR |
| Operating Margin (TTM) Profitability | 0.0% | -315.9% | Higher Margin | ATYR |
| Net Profit Margin Profitability | 0.0% | -282.2% | Higher Margin | ATYR |
| Return on Equity (ROE) Capital Efficiency | -93.7% | -47.6% | Higher ROE | CCCC |
| 52-Week Range Position Momentum | 62% ($0โ$8) | 25% ($2โ$5) | Stronger Trend | ATYR |
| Beta / 30D Volatility Risk Regime | -9.67ฮฒ ยท 13806% Vol | 1.46ฮฒ ยท 67% Vol | Lower Realized Risk | CCCC |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 47.7 / 100 (HOLD) | Higher Composite | CCCC |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ATYR vs CCCC Buy Guide
ATYR
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
36th %ile
IV Regime
Balanced (25thโ60th %ile)
CCCC
BREAKDOWN
118d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
3rd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ATYR nor CCCC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.